SPECIAL NOTICE
We are working on upgrading our websites and despite our best endeavours have experienced census type calamities for almost a week now. Our apologies, we hope to have all problems resolved by Monday August 15th.
SEARCH LISTED COMPANY
Any AUS or NZ company
SEARCH PRIVATE COMPANY
SEARCH FUNDS
Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:
|
|
07 December 2021
| Name: | PHARMAXIS LTD (PXS) |
| ISIN: | AU000000PXS5 |
| Date of Listing: | 10 November 2003 |
Stock Exchange Status: (updated daily)
This entity is currently listed and quoted on the Australian Securities Exchange.Legal Status: (updated monthly)
ACN: 082 811 630ABN: 75 082 811 630
Registration Date: 29 May 1998
Capital Gains Tax (CGT) Status: (updated at least quarterly)
To crystallise a capital gain or capital loss on your securities in this entity, you are able to sell your securities on-market in the normal manner. If you determine that the market in your securities is illiquid and you still wish to crystallise a capital gain or loss, kindly contact deListed at admin@delisted.com.au for suggestions as to how you might proceed.
Updates, corrections, disagreements please email to admin@delisted.com.au
Further information: deListed and InvestoGain are operated by Investogain Pty Limited which is licensed by ASIC as an Australian Financial Services Licensee (AFSL 334036). deListed acquires only securities that it deems to be of little or no value, in circumstances where the holder is unable to sell their securities on-market in the normal manner. This service has been provided online via the company’s website www.delisted.com.au since 2004.
Getting advice: Information provided in this section is of a general nature and applicable only to Australian tax residents who hold their investments on capital account (ie for long-term investment purposes). It has been prepared without taking into account your financial needs or tax situation. Before acting on the information, deListed suggests that you consider whether it is appropriate for your circumstances and recommends that you seek independent legal, financial, or taxation advice.
Disclaimer: The information provided above is to the best of our knowledge accurate as of today. But you should bear in mind that it is of a general nature and does not constitute financial or tax advice. Investogain Pty Limited accepts no liability for any loss arising from reliance on this information, including reliance on information that is no longer current.
Computershare, Level 3, 60 Carrington Street, Sydney NSW 2000
Tel : +61 (0)3 9415 4000 or 1300 850 505 (within Australia)Expand this box to read and print
the suspension of trading in the securities of Pharmaxis Ltd (the "Company") will be lifted immediately, following receipt of an announcement regarding Bronchitol | 24/10/2011 |
Pharmaxis (ASX: PXS) today announced the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a Marketing Authorisation for Bronchitol, clearing the way for the product to be used in Europe "for the treatment of cystic fibrosis in adults as an add?on therapy to best standard of care." | 24/10/2011 |
company expects to receive definitive notification of the outcome of the reexamination of Bronchitol for the treatment of cystic fibrosis from the European Committee for Medicinal Products for Human Use on the evening of Friday 21 October 2011 (Australian time). The Company therefore anticipates making an announcement concerning the reexamination by 8.30am Monday 24 October 2011. That announcement will have the effect of ending the current voluntary suspension of the Company's shares | 21/10/2011 |
the securities of Pharmaxis Ltd (the "Company") will be suspended from quotation immediately, at the request of the Company, pending the release of an announcement | 20/10/2011 |
the suspension of trading in the securities of Pharmaxis Ltd (the "Company") will be lifted immediately, following receipt of an announcement regarding Bronchitol | 24/10/2011 |
Pharmaxis (ASX: PXS) today announced the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a Marketing Authorisation for Bronchitol, clearing the way for the product to be used in Europe "for the treatment of cystic fibrosis in adults as an add?on therapy to best standard of care." | 24/10/2011 |
company expects to receive definitive notification of the outcome of the reexamination of Bronchitol for the treatment of cystic fibrosis from the European Committee for Medicinal Products for Human Use on the evening of Friday 21 October 2011 (Australian time). The Company therefore anticipates making an announcement concerning the reexamination by 8.30am Monday 24 October 2011. That announcement will have the effect of ending the current voluntary suspension of the Company's shares | 21/10/2011 |
the securities of Pharmaxis Ltd (the "Company") will be suspended from quotation immediately, at the request of the Company, pending the release of an announcement | 20/10/2011 |
Your browser may reflect a date of printing in American format.
Purchases Sales
| DATE | DIRECTOR | NUMBER | PRICE | AMOUNT |
|---|---|---|---|---|
| 03/05/2021 | Malcolm McComas | 500,000 | $0.087 | $43,500 |
| 02/12/2016 | Malcolm McComas | 200,000 | $0.271 | $54,167 |
| 29/09/2016 | Gary Phillips | -400,000 | $0.277 | $110,636 |
| 29/10/2013 | Simon Buckingham | 200,000 | $0.124 | $24,854 |
| 02/05/2013 | Gary Phillips | 60,000 | $0.155 | $9,300 |
| NAME | TITLE | DATE OF APPT |
|---|---|---|
| Malcolm McComas | Non Exec Chairman, Independent Director | 07/04/2003 |
| Gary Phillips | CEO, Executive Director | 12/03/2013 |
| David McGarvey | CFO, Company Secretary | 01/12/2002 |
| Will Delaat | Independent Director | 23/06/2008 |
| Kathleen Metters | Non Exec Director | 07/06/2017 |
| Neil Graham | Non Exec Director | 04/05/2020 |
Date of first appointment, title may have changed.
| NAME | TITLE | DATE OF APPOINTMENT | DATE OF RESIGNATION |
|---|---|---|---|
| Edward Rayner | Non Exec Director | 17/09/2018 | 14/08/2020 |
| Simon Buckingham | Independent Director | 25/07/2012 | 22/11/2018 |
| Richard van den Broek | Director | 07/04/2009 | 19/09/2013 |
| John Villiger | Director | 15/11/2006 | 19/09/2013 |
| Alan Robertson | CEO, Director | 25/07/2000 | 12/03/2013 |
| Denis Hanley | Chairman, Independent Director | 24/10/2001 | 01/05/2012 |
| Peter Farrell | Independent Director | 16/03/2006 | 21/10/2009 |
| Charles Kiefel | Non Exec Director | 19/12/2007 | |
| Brigitte Smith | Non Exec Director | 26/10/2006 | |
| Carrie Hillyard | Non Exec Director | 11/04/2006 | |
| Brett Charlton | Executive | 01/06/1998 | 20/03/2006 |
Date of first appointment, title may have changed.
Contact Us | Financial Services Guide | Privacy Policy
This website is owned and operated by Investogain Pty Limited.
ABN 88 129 443 447 | AFSL 334036
Information provided is of a general nature and not for trading or advice.
Copyright © 2002-2021 Investogain Pty Limited. All rights reserved.
